Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.

Lung cancer (Amsterdam, Netherlands) - 1 Dec 2013

Grabauskiene Svetlana, Bergeron Edward J, Chen Guoan, Chang Andrew C, Lin Jules, Thomas Dafydd G, Giordano Thomas J, Beer David G, Morgan Meredith A, Reddy Rishindra M

Abstract excerpt

OBJECTIVE: Overexpression of checkpoint kinase 1 (CHK1) is associated with poorer patient outcome and therapeutic resistance in multiple tumor models. Inhibition of CHK1 has been proposed as a strategy to increase the effectiveness of chemotherapeutic agents, especially in p53-deficient tumors. In this study, we evaluated the effects of a novel CHK1 inhibitor, MK-8776, in combination with pemetrexed (PMX) on cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Checkpoint Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Glutamates

Share to Guanine

Share to Pemetrexed

Share to Pyrazoles

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 24113549
DOI: 10.1016/j.lungcan.2013.09.010
PMCID: PMC4073640

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.PMID 24113549Read ↗

Chk1 Inhibitors for Novel Cancer TreatmentSemantic proximity Read ↗

Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer CellsSemantic proximity Read ↗

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastomaSemantic proximity Read ↗

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancerSemantic proximity Read ↗

Synergistic cytotoxicity with Chk1/Chk2-inhibitor prexasertib in small cell lung cancer following lurbinectedin-induced G2/M-checkpoint activationSemantic proximity Read ↗

Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibitionSemantic proximity Read ↗

Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer CellsSemantic proximity Read ↗

Chk1 as a new therapeutic target in triple-negative breast cancerSemantic proximity Read ↗

Unleashing Chk1 in cancer therapySemantic proximity Read ↗

Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma CellsSemantic proximity Read ↗

CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy responseSemantic proximity Read ↗

Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell deathSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.